News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
498 Results
Type
Article (76)
Press Release (422)
Section
Business (189)
Deals (46)
Drug Delivery (1)
Drug Development (121)
FDA (10)
Job Trends (11)
News (308)
Policy (19)
Tag
Academia (2)
Alliances (35)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (1)
Approvals (10)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (7)
Cardiovascular disease (3)
Cell therapy (2)
Clinical research (72)
Collaboration (2)
COVID-19 (3)
C-suite (1)
Duchenne muscular dystrophy (11)
Earnings (84)
Editorial (1)
Events (128)
FDA (10)
Gene therapy (14)
GLP-1 (1)
Government (2)
Healthcare (3)
Immunology and inflammation (2)
Infectious disease (3)
Intellectual property (1)
IPO (34)
Job creations (4)
Layoffs (2)
Legal (2)
Mergers & acquisitions (12)
Metabolic disorders (1)
Neurodegenerative disease (3)
Neuroscience (4)
NextGen: Class of 2025 (7)
Non-profit (8)
Northern California (1)
Obesity (1)
Opinion (2)
Patents (2)
People (52)
Phase I (46)
Phase II (58)
Phase III (15)
Pipeline (3)
Policy (3)
Preclinical (7)
Press Release (1)
Rare diseases (8)
Real estate (4)
Regulatory (17)
Special edition (1)
Spinal muscular atrophy (1)
Startups (4)
Tariffs (1)
The Weekly (2)
United States (12)
Date
Last 30 days (1)
Last 365 days (43)
2025 (17)
2024 (47)
2023 (55)
2022 (70)
2021 (75)
2020 (66)
2019 (46)
2018 (47)
2017 (19)
2016 (13)
2015 (25)
2014 (10)
2013 (5)
2012 (2)
2011 (1)
Location
Asia (9)
Australia (1)
California (2)
China (1)
Europe (32)
Florida (1)
Georgia (4)
Illinois (1)
Maryland (1)
Massachusetts (2)
New Jersey (2)
Northern California (1)
498 Results for "regenxbio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku
In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.
January 14, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
Business
REGENXBIO Announces Leadership Transition
REGENXBIO Inc. announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024.
June 12, 2024
·
8 min read
Press Releases
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
January 13, 2025
·
7 min read
BioCapital
REGENXBIO to Participate in Upcoming May 2024 Investor Conferences
REGENXBIO Inc. announced it will participate in the following upcoming investor conferences.
May 10, 2024
·
1 min read
BioCapital
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
June 5, 2024
·
1 min read
Business
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO Inc. announced financial results for the first quarter ending March 31, 2024.
May 8, 2024
·
13 min read
BioCapital
REGENXBIO to Participate in Upcoming March 2024 Investor Conferences
REGENXBIO Inc. announced it will participate the following upcoming investor conferences.
March 11, 2024
·
1 min read
Drug Development
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
June 24, 2024
·
10 min read
BioCapital
REGENXBIO to Participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
March 27, 2024
·
1 min read
1 of 50
Next
